Evaluation the benefits of additional radiotherapy for gastric cancer patients after D2 resection using CT based radiomics.
Radiol Med
; 128(6): 679-688, 2023 Jun.
Article
em En
| MEDLINE
| ID: mdl-37188857
ABSTRACT
OBJECTIVES:
The value of adding radiotherapy (RT) is still unclear for patients with gastric cancer (GC) after D2 lymphadenectomy. The purpose of this study is to predict and compare the overall survival (OS) and disease-free survival (DFS) of GC patients treated by chemotherapy and chemoradiation based on contrast-enhanced CT (CECT) radiomics.METHODS:
A total of 154 patients treated by chemotherapy and chemoradiation in authors' hospital were retrospectively reviewed and randomly divided into the training and testing cohorts (73). Radiomics features were extracted from contoured tumor volumes in CECT using the pyradiomics software. Radiomics score and nomogram with integrated clinical factors were developed to predict the OS and DFS and evaluated with Harrell's Consistency Index (C-index).RESULTS:
Radiomics score achieved a C index of 0.721(95%CI 0.681-0.761) and 0.774 (95%CI 0.738-0.810) in the prediction of DFS and OS for GC patients treated by chemotherapy and chemoradiation, respectively. The benefits of additional RT only demonstrated in subgroup of GC patients with Lauren intestinal type and perineural invasion (PNI). Integrating clinical factors further improved the prediction ability of radiomics models with a C-index of 0.773 (95%CI 0.736-0.810) and 0.802 (95%CI 0.765-0.839) for DFS and OS, respectively.CONCLUSIONS:
CECT based radiomics is feasible to predict the OS and DFS for GC patients underwent chemotherapy and chemoradiation after D2 resection. The benefits of additional RT only observed in GC patients with intestinal cancer and PNI.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Gástricas
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Radiol Med
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
China